Prostate-specific antigen and early detection of prostate cancer

Tumor Biology

Volumn 18, Issue 2, 1997, Pages 123-134

  Chu, Ming ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

Early detection; Prostate cancer; Prostate specific antigen; Screening

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

CANCER SCREENING; EARLY DIAGNOSIS; HUMAN; MALE; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW;

EID: 0031026446     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1159/000218023     Document Type: Article

References (53)

1. Chu TM: Historical and fundamental aspects of prostate specific antigen; in Catalona WJ, Coffey DS, Karr JP (eds): Clinical Aspects of Prostate Cancer: Assessment of New Diagnostic and Management Procedures, New York, Elsevier, 1989, pp 124-127.
2. Chu TM: Prostate specific antigen: The historical perspective, McGill J Med, in press.
3. Wang MC, Valenzuela LA, Murphy GP, Chu TM: Purification of a human prostate specific antigen, Invest Urol 1979;17:159-163.
4. Wang MC, Valenzuela LA, Murphy GP, Chu TM: A simplified purification procedure for human prostate antigen, Oncology 1982;39:1-5.
5. Papsidero LD, Wang MC, Valenzuela LA, Murphy GP, Chu TM: A prostate antigen in sera of prostatic cancer patients, Cancer Res 1980; 40:2428-2432.
6. Kuriyama M, Wang MC, Papsidero LD, Killian CS, Shimano T, Valenzuela LA, Nishiura T, Murphy GP, Chu TM: Quantitation of prostate specific antigen in serum by a sensitive enzyme immunoassay, Cancer Res 1980;40:4658-4662.
7. Chu TM, Wang MC, Lee CL, Killian CS, Valenzuela LA, Wajsman Z, Slack NH, Murphy GP: Enzyme markers for prostate cancer, Cancer Detect Prev 1979;2:693-706.
8. Kuriyama M, Wang MC, Lee CL, Killian CS, Papsidero LD, Inaji H, Loor RM, Lin MF, Nishiura T, Slack NH, Murphy GP, Chu TM: Multiple marker evaluation in prostate cancer using tissue specific antigens, J Natl Cancer Inst 1982;68: 99-103.
9. Kuriyama M, Wang MC, Lee CL, Papsidero LD, Killian CS, Inaji H, Slack NH, Nishiura T, Murphy GP, Chu TM: Use of human prostate-specific antigen in monitoring prostate cancer, Cancer Res 1981;41: 3874-3876.
10. Pontes JE, Chu TM, Slack NH, Karr JP, Murphy GP: Scrum prostate antigen measurement in localized prostate cancer: Correlation with clinical course, J Urol 1982; 128: 1216-1218.
11. Wang MC, Loor RM, Li SL, Chu TM: Physico-chemical characterization of prostate specific antigen purified from human prostate gland and seminal plasma, Int Res Commun System Med Sci 1983; 11:327-328.
12. Ban Y, Wang MC, Watt KW, Loor RM, Chu TM: The proteolytic activity of human prostate-specific antigen, Biochem Biophys Res Commun 1984;123:482-488.
13. Watt K, Lee P, M’Timkulu T, Chan W, Loor RM: Human prostate-specific antigen: Structural and functional similarity with serine protease, Proc Natl Acad Sci USA 1986; 83:3166-3170.
14. Wang MC, Kuriyama M, Papsidero LD, Loor RM, Valenzuela LA, Murphy GP, Chu TM: Prostate antigen of human cancer patients; in Busch H, Yeoman LC (eds): Methods in Cancer Research, New York, Academic Press, 1982, vol 19, pp 179- 197.
15. Papsidero LD, Croghan GA, Wang MC, Kuriyama M, Johnson EA, Valenzuela LA, Chu TM: Monoclonal antibody (F5) to human prostate specific antigen, Hybridoma 1983;2:139-147.
16. Chu TM, Kawinski E, Hibi N, Croghan G, Wiley J, Killian CS, Corral D: Prostate-specific antigenic domain of human prostate-specific antigen identified with monoclonal antibodies, J Urol 1989; 141:152- 156.
17. Papsidero LD, Kuriyama M, Wang MC, Horoszewicz JS, Lcong SS, Valenzuela LA, Murphy GP, Chu TM: Prostate specific antigen: A marker for human prostatic epithelial cells, J Natl Cancer Inst 1981;66: 37-44.
18. Papsidero LD, Wang MC, Kuriyama M, Horoszewicz JS, Leong SS, Croghan GA, Valenzuela LA, Murphy GP, Chu TM: Human prostate epithelial cell-specific antigen; in Murphy GP (ed): The Prostatic Cell, New York, Liss, 1981, pp 435-443.
19. Wang MC, Papsidero LD, Kuriyama M, Valenzuela LA, Murphy GP, Chu TM: Prostate antigen: A new potential marker for prostate cancer, Prostate 1981;2:89-96.
20. Nadji M, Tabci SZ, Castro A, Chu TM, Wang MC, Murphy GP, Morales AR: Prostatic specific antigen: An immunohistologic marker for prostatic neoplasms, Cancer 1981: 48:1229-1232.
21. Cooner WH, Moisey BR, Rutherford CL, Beard JH, Pond HS, Bass NB, Terry WJ: Clinical application of transrectal ultrasonography and prostate-specific antigen in the search for prostate cancer, J Urol 1988;139:758-761.
22. Catalona WJ, Smith DD, Ratliff TL, Dodds KM, Coplen DE, Yuan JJJ, Petros JA, Andriole GL: Measurement of prostate-specific antigen in serum as a screening test for prostate cancer, N Engl J Med 1991,324: 1156-1161.
23. Brawcr MK, Chetner MP, Beatie J, Buchner DM, Vessela RL, Lange PH: Screening for prostatic carcinoma with prostate-specific antigen, J Urol 1992;147:841-845.
24. Catalona WJ, Smith DS, Ratliff TL, Basler JW: Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening, JAMA 1993:270: 948-954.
25. Littrup PJ, Lee F, Mettlin CJ: Prostate cancer screening: Current trends and future implications, CA Cancer J Clin 1992;42:198-211.
26. Mettlin CJ, Jones GW, Averette H, Gusberg SB, Murphy GP: Defining and updating the American Cancer Society guidelines for the cancer-related checkup: Prostate and endometrial cancer, CA Cancer J Clin 1993:43:42-46.
27. Potosky AL, Miller BA, Albertsen PC, Barnett BS, Kramer BS: The role of increasing detection in the rising incidence of prostate cancer, J Natl Cancer Inst 1995:273:548-552.
28. Jacobsen SJ, Katusic SK, Bergstralh EJ, Oesterling JE, Ohrt D, Klee GG, Chute CG, Liebcr MM: Incidence of prostate cancer diagnosis in the eras before and after scrum prostate-specific antigen testing, J Natl Cancer Inst 1995;274:1445-1449.
29. Bowersox J: Experts debate PSA screening for prostate cancer, J Natl Cancer Inst 1992:84:1856-1857.
30. Kramer BS, Brown ML, Prorok PC, Potosky AL, Gohagan JK: Prostate cancer screening: What we know and what we need to know, Ann Intern Med 1993; 119:914-923.
31. Chu TM: Prostate-specific antigen in screening of prostate cancer, J Clin Lab Anal 1994;8:323-326.
32. Slawin KM, Ohori M, Dillioglugil O, Scardino PT: Screening for prostate cancer: An analysis of the early experience, CA Cancer J Clin 1995; 45:134-147.
33. Catalona WJ, Richie JP, Ahmann FR, Hudson MA, Scardino PT, Flanigan RC, deKemion JB, Ratliff TL, Kavoussi LR, Dalkin BL, Waters WB, MacFarlcnc MT, South-wick PC: Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: Results of multicenter clinical trial of6,630 men, J Urol 1994;151:1283-1290.
34. Smith DS, Catalona WJ: The nature of prostate cancer detected through prostate specific antigen based screening, J Urol 1994:152:1732- 1736.
35. Brawcr MK, Bcatic J, Wener MH, Vessella RL, Preston SD, Lange PH: Screening for prostate carcinoma with prostate specific antigen: Results of the second year, J Urol 1993; 150:106-109.
36. Shrader FH, Danthuis RA, Kirkels WJ, dcKoning HJ, Kranse R, Nus HG, Blijenberg BG: European randomized study of screening for prostate cancer - the Rotterdam pilot study, Int J Cancer 1996,65:145-151.
37. Feneley MR, Kirby MG, McNicho-las T, McLean A, Webb JA, Kirby RS: Screening in general practice, Cancer Surv 1995;23:115-125.
38. Shimizu TS, Uchida T, Satoh J, Imai K, Yamanaka H: Prostate-specific antigen in mass screening for carcinoma of the prostate, Int J Urol 1995;2:257-260.
39. Egawa S, Suyama K, Ohori M, Ka-wakami T, Kuwao S, Hirokado K, Hirano S, Yokoyama E, Uchida T, Koshiba K: Early detection of prostate cancer, Results of a prostate specific antigen-based detection program in Japan, Cancer 1995;76: 463-472.
40. Pode D, Shapiro A, Lebensart P, Mcretyk S, Katz G, Barak V: Screening for prostate cancer, Isr J Med Sei 1995;31:125-128.
41. Auvinen A, Tammela T, Stenman UH, Uusi-Erkkila IU, Leinonen J, Chroder FH, Hakama M: Screening for prostate cancer using serum prostate-specific antigen: A randomised, population-based pilot study in Finland, Br J Cancer 1996:74:568- 572.
42. Epstein JI, Walsh PC, Carmichael M, Brendler CB: Pathologic and clinical findings to predict tumor extent of nonpalpable (stage Tic) prostate cancer, JAMA 1994;271:368-374.
43. Walsh PC: Prostate cancer kills: Strategy to reduce deaths, Urology 1994;44:463-466.
44. Ohiro M, Scardino PT: Early detection of prostate cancer: The nature of cancers detected with current diagnostic tests, Semin Oncol 1994; 21:522-526.
45. Chodak GW, Thisted RA, Gerber GS, Johansson J, Adolfsson J, Jones G, Chisholm GD, Moskovitz B, Livrc PP, Warner J: Results of conservative management of clinically localized prostate cancer, N Engl J Med 1994;330:242-248.
46. Seidman H, Mushinski MH, Gclb SK, Silverberg E: Probabilities of eventually developing or dying of cancer - United States, 1985, CA Cancer J Clin 1985;35:36-56.
47. Lubkc WL, Optenberg SA, Thompson IM: Analysis of the first-year cost of a prostate cancer screening and treatment program in the United States, J Natl Cancer Inst 1994:86:1790-1792.
48. Mettlin C, Murphy GP, Ray P, San-berg A, Toi A, Chcsley A, Babaian R, Badalamcnt R, Kane RA, Lee F, Investigators of the American Cancer Society-National Prostate Cancer Detection Project: Results from multiple examinations using trans-rectal ultrasound, digital rectal examination, and prostate specific antigen, Cancer 1993;71:891-898.
49. Smith DS, Catalona WJ, Hersch-mann JD: Longitudinal screening for prostate cancer with prostate-specific antigen, JAMA 1996,276: 1309-1315.
50. Oesterling JE: Prostate-specific antigen, Improving its ability to diagnose early prostate cancer, J Natl Cancer Inst 1992;267:2236-2238.
51. Gohagan JK, Prorok PC, Kramer BS, Hayes RB, Cornett JE: The prostate, lung, colorectal, and ovarian cancer screening trial of the National Cancer Institute, Cancer 1995;75:1869-1873.
52. Wilt TJ, Barry MJ: The prostate cancer intervention versus observation trial (PIVOT), Urol Int 1995;3: 16-17.
53. Krahn MD: The current PSA screening debate is not about PSA, Clin Lab News, February 1995, p 7.